Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 1999

View Archived Issues

Sanofi-Synthelabo and LEK form joint venture for Slovenia, Croatia

Nymox confirms importance of spherons in AD etiology

Abgenix and CuraGen to develop genomics-based human antibody drugs

Sankyo accelerates antiangina drug development

Bivalirudin: a new gold standard in the field of anticoagulants

Nippon Chemiphar withdraws Leminon 80 application for approval in Japan

Hoechst DMARD now in U.K. pharmacies

DuPont focuses on development of MMP inhibitors selective for TNF production

Orphan Europe launches treatment for rare metabolic disorder in U.K.

Orally active piperidine compounds from Novo Nordisk selectively stimulate GH release

NCI commences trials of Genta's bcl-2 antisense compound in relapsed cancer patients

Viral chimeras for stimulating anti-HIV-1 immune response

The Rockefeller University designs inhibitors of enzyme involved in melatonin biosynthesis

Novel 9-substituted hypoxanthines inhibit MAO and regulate calcium channel function

Targeted Genetics presents advances in synthetic gene delivery technologies

Humanized anti-Fas antibody with potential as a safe and effective therapeutic for RA

Concor COR cleared for marketing in Germany as heart failure treatment

Chinese investigators pursue new radiosensitizing agents

Water-soluble anticancer oxysterols designed at Shenyang Pharmaceutical University

Millennium delivers ninth target to Wyeth-Ayerst for screening

Indian scientists explore mechanism of cardioprotective effect of PAF antagonist

ODAC votes for approval of Targretin for one indication, against approval for another

Herbomineral preparation shows efficacy in animal model of BPH

New analgesic from CDRI has much less influence on behavior compared to morphine

FDA advisory committee recommends approval of Celebrex as adjunctive therapy for FAP

Role for antioxidant in the treatment of ulcers: experimental results presented at Indian congress

InKine initiates phase II multicenter trial for IBD treatment

Fidia reports good business and R&D prospects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...